BRPI0607897A2 - compostos oxindol e sua utilização como agentes terapêuticos - Google Patents

compostos oxindol e sua utilização como agentes terapêuticos

Info

Publication number
BRPI0607897A2
BRPI0607897A2 BRPI0607897-4A BRPI0607897A BRPI0607897A2 BR PI0607897 A2 BRPI0607897 A2 BR PI0607897A2 BR PI0607897 A BRPI0607897 A BR PI0607897A BR PI0607897 A2 BRPI0607897 A2 BR PI0607897A2
Authority
BR
Brazil
Prior art keywords
compounds
therapeutic agents
oxindole compounds
oxindole
pain
Prior art date
Application number
BRPI0607897-4A
Other languages
English (en)
Inventor
Mikhail Chafeev
Jianmin Fu
Jianyu Sun
Tom Hsieh
Sultan Chowdhury
Robert Fraser
Duanjie Hou
Rajender Kamboj
Shifeng Liu
Shaoyi Sun
Serguei Sviridov
Mehran Seid Bagherzadeh
Nagasree Chakka
Vandna Raina
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of BRPI0607897A2 publication Critical patent/BRPI0607897A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSTOS OXINDOL E SUA UTILIZAçãO COMO AGENTES TERAPêUTICOS. A invenção está direcionada a compostos oxindol que são uteis para o tratamento e/ou prevencao de doenças ou condições mediadas por canal sódio, tal como dor. Composições farmacêuticas que compreendem os compostos e métodos de utilizacao dos compostos são também revelados.
BRPI0607897-4A 2005-04-20 2006-04-20 compostos oxindol e sua utilização como agentes terapêuticos BRPI0607897A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67342105P 2005-04-20 2005-04-20
PCT/US2006/014865 WO2006113864A2 (en) 2005-04-20 2006-04-20 Oxindole compounds and their uses as therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0607897A2 true BRPI0607897A2 (pt) 2009-10-20

Family

ID=36694168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607897-4A BRPI0607897A2 (pt) 2005-04-20 2006-04-20 compostos oxindol e sua utilização como agentes terapêuticos

Country Status (11)

Country Link
US (1) US20070105820A1 (pt)
EP (1) EP1877378A2 (pt)
JP (1) JP2008536941A (pt)
CN (1) CN101213174A (pt)
AR (1) AR056317A1 (pt)
AU (1) AU2006236273A1 (pt)
BR (1) BRPI0607897A2 (pt)
CA (1) CA2605059A1 (pt)
MX (1) MX2007013175A (pt)
TW (1) TW200716546A (pt)
WO (1) WO2006113864A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046046A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
CA2666143A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
AR063280A1 (es) * 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
EP2155260A1 (en) * 2007-06-14 2010-02-24 Hammersmith Imanet, Ltd Measurement of neural activity
JP2010540628A (ja) 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としてのｎ−置換されたオキシインドリン誘導体
JP2010540631A (ja) * 2007-10-04 2010-12-24 メルク・シャープ・エンド・ドーム・コーポレイション カルシウムチャネル遮断薬としてのｎ−置換されたオキシインドリン誘導体
CN105218565A (zh) * 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2763931A1 (en) * 2009-06-10 2010-12-16 Abbott Gmbh & Co. Kg Use of substituted oxindole derivatives for the treatment and prophylaxis of pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011056985A2 (en) * 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
CN102656147A (zh) * 2009-12-11 2012-09-05 霍夫曼-拉罗奇有限公司 可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US20130137728A1 (en) * 2010-03-24 2013-05-30 MUSC Foundation for Research and Development Compositions and Methods for the Treatment of Degenerative Diseases
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
WO2012003392A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (pt) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
ES2604958T3 (es) 2011-10-28 2017-03-10 Vanderbilt University Análogos de 2-(4-heterociclilbencil)isoindolin-1-ona sustituidos como moduladores alostéricos positivos del receptor muscarínico de acetilcolina M1
US9073935B2 (en) 2011-11-11 2015-07-07 Vanderbilt University Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
CN102516151B (zh) * 2011-11-11 2013-09-11 华东师范大学 一种3-取代-3-羟基吲哚酮衍生物及其制备方法和应用
US9029563B2 (en) 2012-01-06 2015-05-12 Vanderbilt University Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
WO2013106795A1 (en) 2012-01-12 2013-07-18 Vanderbilt University Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
AU2013245812B2 (en) 2012-04-12 2017-04-06 Georgetown University Methods and compositions for treating Ewing's sarcoma family of tumors
MX375169B (es) * 2014-06-26 2025-03-06 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona.
CN111777596A (zh) 2014-10-09 2020-10-16 英克特诺治疗公司 吲哚酮化合物及其用途
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
AU2016254049A1 (en) * 2015-04-30 2017-11-02 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof
TW201722938A (zh) * 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
RU2727179C2 (ru) 2015-11-06 2020-07-21 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она
EP3371170B1 (en) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
SG11201806153QA (en) 2016-01-20 2018-08-30 Chemocentryx Inc 2-oxindole compounds
KR102375929B1 (ko) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. 인돌린 유사체 및 이의 용도
US10159660B2 (en) 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
FR3067028B1 (fr) * 2017-06-06 2019-07-12 Adpuerivitam Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
CN111423351B (zh) * 2019-01-09 2024-03-29 中国科学技术大学 手性铜复合物及其制备方法和应用
EP4041229A4 (en) * 2019-10-07 2023-10-25 D.E. Shaw Research, LLC Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
TW202229254A (zh) 2020-09-30 2022-08-01 日商拉夸里亞創藥股份有限公司 作為crhr2拮抗劑之3-羥基吲哚酮衍生物
AU2024359022A1 (en) * 2023-10-10 2026-04-09 Jazz Pharmaceuticals Research Uk Limited Cannabinoid compounds and uses thereof
CN117777002A (zh) * 2023-12-04 2024-03-29 华南理工大学 一种3,3-二取代氧化吲哚衍生物的不对称合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) * 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE2113343A1 (de) * 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US4670566A (en) * 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4440785A (en) * 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
US4690943A (en) * 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US5116854A (en) * 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5776936A (en) * 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) * 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
AT400950B (de) * 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
US5763471A (en) * 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
FR2740136B1 (fr) * 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
HUP9600855A3 (en) * 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998031378A1 (de) * 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US6726285B2 (en) * 2000-07-03 2004-04-27 Herman Miller, Inc. Cellular chair construction
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
WO2003016276A2 (en) * 2001-08-14 2003-02-27 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
US7205407B2 (en) * 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
WO2003078394A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
CN1780626A (zh) * 2003-05-16 2006-05-31 辉瑞产品公司 双相性精神障碍和相关症状的治疗
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.

Also Published As

Publication number Publication date
CA2605059A1 (en) 2006-10-26
AU2006236273A1 (en) 2006-10-26
WO2006113864A2 (en) 2006-10-26
EP1877378A2 (en) 2008-01-16
JP2008536941A (ja) 2008-09-11
WO2006113864A3 (en) 2007-01-25
CN101213174A (zh) 2008-07-02
US20070105820A1 (en) 2007-05-10
AR056317A1 (es) 2007-10-03
TW200716546A (en) 2007-05-01
MX2007013175A (es) 2008-01-18

Similar Documents

Publication Publication Date Title
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
EA201400111A1 (ru) Ингибиторы mek и способы их применения
EP2114925A4 (en) AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
PT1611088E (pt) Hidroxamatos como agentes terapêuticos
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
UY26130A1 (es) Compuestos para tratar la obesidad
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20073776L (no) Trisykliske delta-opioidmodulatorer
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
BRPI0508537A (pt) moduladores do canal de ìon
ATE542531T1 (de) Nitrofuran-verbindungen zur behandlung von krebs und angiogenese

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]